Companies › ALKS

ALKERMES PLC (ALKS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001520262 · EDGAR filings · Updated 2026-07-28

ALKERMES PLC (ALKS) has reported institutional ownership of 104.6%, with 385 institutional managers holding positions valued at $6.18B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Filings this week (3)

• 2026-07-28 — Employee-plan registration (S-8) filed
• 2026-07-28 — Quarterly report (10-Q) filed
• 2026-07-28 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-08 — Current report (8-K) filed
• 2026-07-06 — Insider transaction reported (Form 4)
• 2026-07-06 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ALKERMES PLC has 385 institutional holders and institutional ownership of 104.6%.

Insider activity

Insiders reported 98 transactions (0 buys, 17 sells) across 14 reporting insiders, with a net reported value of −$4.45M.

Data flags from SEC filings

Related companies

AXSOME THERAPEUTICS INC. (AXSM) · MIRUM PHARMACEUTICALS INC (MIRM) · GLAUKOS CORP (GKOS) · CG ONCOLOGY INC (CGON) · CENTESSA PHARMACEUTICALS PLC (CNTA) · XENON PHARMACEUTICALS INC (XENE)